JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

Accueil・Liste d'Actions・Sanofi

Sanofi

Fermé

43.37 0.18

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

43.08

Max

43.52

Chiffres clés
By Trading Economics
Revenu	2.4B 1.6B
Ventes	-961M 11B
P/E Moyenne du Secteur	19.885 67.147
BPA	1.102
Marge bénéficiaire	14.354
Employés	74,846
EBITDA	-1.1B 2.7B

Recommandations
By TipRanks
Recommandations	Neutre
Prévisions sur 12 Mois	+22.26% upside

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	-11B 104B
Ouverture précédente	43.19
Clôture précédente	43.37

Score Technique

By Trading Central

Confiance

Strong Bearish Evidence

51.665 / 52.38 Support & Résistance

Sanofi Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

23 avr. 2026, 06:12 UTC

Résultats

Sanofi Posts Higher Sales Amid Leadership Transition

12 févr. 2026, 12:40 UTC

Principaux Mouvements du Marché

Sanofi Shares Fall After CEO Change

29 janv. 2026, 11:35 UTC

Résultats

Sanofi Remains Committed to Vaccines After Mixed Year for Drug Pipeline -- Update

29 avr. 2026, 12:01 UTC

Résultats

Regeneron Earnings Beat Expectations. Upcoming Cancer Data Matter More for the Stock. -- Barrons.com

27 avr. 2026, 09:32 UTC

Market Talk

Résultats

Sanofi's Dupixent Sales Growth Set to Moderate -- Market Talk

27 avr. 2026, 09:19 UTC

Market Talk

Sanofi's New CEO Needs to Be Clear on Strategy -- Market Talk

23 avr. 2026, 05:34 UTC

Résultats

Sanofi: 2026 Expectations Are at Constant Exchange Rates

23 avr. 2026, 05:34 UTC

Résultats

Sanofi Sees Business EPS Growth Slightly Faster Than Sales in 2026

23 avr. 2026, 05:34 UTC

Résultats

Sanofi Sees Sales Growth by a High Single-Digit Percentage in 2026

23 avr. 2026, 05:34 UTC

Résultats

Sanofi Backs 2026 View

23 avr. 2026, 05:33 UTC

Résultats

Sanofi 1Q Business Net Pft EUR2.26B

23 avr. 2026, 05:33 UTC

Résultats

Analysts Saw Sanofi 1Q Business Oper Pft at EUR2.85B

23 avr. 2026, 05:33 UTC

Résultats

Sanofi 1Q Business Oper Pft EUR2.97B

23 avr. 2026, 05:32 UTC

Résultats

Analysts Saw Sanofi 1Q Net Sales at EUR10.22B

23 avr. 2026, 05:32 UTC

Résultats

Sanofi 1Q Net Sales Rose 14% on Year at Constant Exchange Rates

23 avr. 2026, 05:31 UTC

Résultats

Sanofi 1Q Net Sales EUR10.51B

10 avr. 2026, 11:12 UTC

Market Talk

Sanofi Investors Might Have to Wait for Update on Strategy -- Market Talk

10 avr. 2026, 10:54 UTC

Market Talk

Sanofi Could Get Boost From Dupixent U.S. Price -- Market Talk

30 mars 2026, 10:40 UTC

Market Talk

Sanofi Shares Fall After Company Reports Second Cancer Case in Trial -- Market Talk

27 mars 2026, 10:40 UTC

Market Talk

AstraZeneca Hits Goal in Lung Disease Where Rivals Missed -- Market Talk

11 mars 2026, 11:02 UTC

Market Talk

Sanofi, Regeneron's Eczema Drug Might Face Competition From Pfizer -- Market Talk

24 févr. 2026, 14:00 UTC

Acquisitions, Fusions, Rachats

This Small-Cap Biotech Stock Is Soaring 35% on Excitement Over Its Prostate Cancer Drug -- Barrons.com

13 févr. 2026, 08:21 UTC

Market Talk

Sanofi's CEO Change Adds to Near-Term Uncertainty -- Market Talk

12 févr. 2026, 15:20 UTC

Résultats

Sanofi Shares Fall After CEO Change -- Update

10 févr. 2026, 14:07 UTC

Acquisitions, Fusions, Rachats

Sanofi Set Out $2.2 Bln Cash Deal for Dynavax Late Last Year

10 févr. 2026, 14:06 UTC

Acquisitions, Fusions, Rachats

Sanofi: Acquisition Includes Dynavax's Hepatitis B Vaccine, Shingles Vaccine Candidate

10 févr. 2026, 14:05 UTC

Acquisitions, Fusions, Rachats

Sanofi Completes Acquisition of Dynavax

10 févr. 2026, 14:00 UTC

Acquisitions, Fusions, Rachats

Press Release: Sanofi Completes The Acquisition Of Dynavax >SAN.FR

6 févr. 2026, 12:35 UTC

Résultats

Biogen Stock Rises Even as Multiple Sclerosis Revenue Tumbles. It Sees Continued Declines in the Portfolio. -- Barrons.com

29 janv. 2026, 13:00 UTC

Market Talk

Résultats

Sanofi Results Encourage, But Pipeline Strategy Should Take Priority -- Market Talk

Comparaison

Variation de prix

Sanofi prévision

Objectif de Prix

By TipRanks

22.26% hausse

Prévisions sur 12 Mois

Moyen 53 USD 22.26%

Haut 57 USD

Bas 50 USD

Basé sur 3 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Neutre

3 ratings

Achat

Maintien

Vente

Basé sur 3 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Score Technique

By Trading Central

51.665 / 52.38Support & Résistance

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.